-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EVJKwX3LY3sSl5Fu10xBpXwjwm1JKVWW/hiluiBfcOZOi+Ck384495ENzcI4Yl9s
 T5Kqft91SW+1alcHYhQD7A==

<SEC-DOCUMENT>0001075880-08-000052.txt : 20080730
<SEC-HEADER>0001075880-08-000052.hdr.sgml : 20080730
<ACCEPTANCE-DATETIME>20080730082629
ACCESSION NUMBER:		0001075880-08-000052
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080730
FILED AS OF DATE:		20080730
DATE AS OF CHANGE:		20080730

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		08977355

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k200807302.htm
<DESCRIPTION>FORM 6K 2008 07 30 2
<TEXT>
<html>
  <head>
    <title>form6k200807302.htm</title>
<!-- Licensed to: Novogen Laboratories Pty Ltd-->
<!-- Document Created using EDGARizer 4.0.6.1 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 5%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5%; FONT-FAMILY: Times New Roman">
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">______________________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For the
month of July, 2008</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140 Wicks
Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(Address
of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf </font>by the undersigned, thereunto duly
authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Ron
Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Date
30 July, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right"><img src="novogenletterhead.jpg" alt="Novogen logo"></div>
    <div>&#160;</div>
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">ASX
&amp; MEDIA RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">30
JULY 2008</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">NOVOGEN
RAISES A$5.5m FOR INVESTMENT IN MARSHALL EDWARDS</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Sydney
Australia : Novogen Limited (ASX: NRT; NASDAQ: NVGN) has raised A$5.5million in
an equity issue to substantial shareholder El Coronado Holdings
LLC&#160;at&#160;&#160;A$1.22 per share.&#160;&#160;This issue is at a premium
to the current Novogen share price.&#160; Following this placement El Coronado
will hold 19.9% of Novogen's issued shares.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
proceeds will be used by Novogen to participate in a US$10million equity raising
being concluded by US subsidiary company Marshall Edwards Inc
(NASDAQ:MSHL).</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
Marshall Edwards Inc announcement to the US market was as follows:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">MARSHALL
EDWARDS, INC. RAISES $10,000,000 IN PUBLIC OFFERING</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Washington
DC; and Sydney Australia &#8211; 30 July, 2008) Marshall Edwards, Inc. (Nasdaq: MSHL)
announced today that it entered into a Securities Subscription Agreement with
Novogen Limited and OppenheimerFunds, Inc. pursuant to which Marshall Edwards
has sold 2,908,295 and 1,700,000 shares of common stock, par value $0.00000002
per share, to Novogen and Oppenheimer, respectively, at a purchase price of
$2.17 per share, the consolidated closing bid price of the Marshall Edwards&#8217;
common stock as quoted by the Nasdaq Market Intelligence Desk at 4:00 PM EST on
28&#160;July,&#160;2008.&#160;&#160;The aggregate proceeds to Marshall Edwards
from the sale of shares of common stock will be $10,000,000 before
expenses.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
shares are registered under the Securities Act of 1933, as amended, pursuant to
an effective shelf registration statement.&#160;&#160;On 30 July, 2008, the
Company filed a Prospectus Supplement to the Registration Statement with the SEC
covering the sale of the shares to Novogen and Oppenheimer pursuant to the
Securities Subscription Agreement.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any
such state.&#160;&#160;The securities may be offered only by means of a
prospectus.&#160;&#160;Copies of the Prospectus Supplement and the accompanying
base Prospectus relating to the offering may be obtained at the SEC&#8217;s website at
http://www.sec.gov.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Marshall Edwards, Inc.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc. is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics.&#160;&#160;These derive from a
flavonoid technology platform, which has generated a number of novel compounds
characterised by broad ranging activity against a range of cancer cell types
with few side effects.&#160;&#160;The combination of anti-tumour cell activity
and low toxicity is believed to be a result of the ability of these compounds to
target an enzyme present in the cell membrane of cancer cells, thereby
inhibiting the production of pro-survival proteins within the
cell.&#160;&#160;Marshall Edwards, Inc. has licensed rights from Novogen Limited
(ASX:NRT) (NasdaqGM:NVGN) to bring three oncology drugs -- phenoxodiol,
triphendiol and NV-143 -- to market globally.&#160;&#160;The Company's lead
investigational drug, phenoxodiol, is in a Phase III multinational multi-centred
clinical trial for patients with recurrent ovarian cancer. More information on
the trial can be found at http://www.OVATUREtrial.com.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc. is majority owned by Novogen Limited (ASX:NRT) (NasdaqGM:NVGN), an
Australian biotechnology company that is specialising in the development of
therapeutics based on a flavonoid technology platform.&#160;&#160;Novogen is
developing a range of therapeutics across the fields of oncology, cardiovascular
disease and inflammatory diseases.&#160;&#160;More information on phenoxodiol
and on the Novogen group of companies can be found at www.marshalledwardsinc.com
and www.novogen.com.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Under US.
law, a new drug cannot be marketed until it has been investigated in clinical
trials and approved by the FDA as being safe and effective for the intended use.
Statements included in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. You should be aware
that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management's current expectations
and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.</font></div>
    </div>
    <div>&#160;</div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenletterhead.jpg
<DESCRIPTION>NOVOGEN LOGO
<TEXT>
begin 644 novogenletterhead.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!E`/P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`JM!<QRW=U`I^>%EW#ZJ"*LUYWJ?B>/PW\6UM[QQ'8ZE8PH
M[MP$D#N$8GTY(/U!/2FE<SJ34+-GHE%%%(T"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHK.UG7-/T"S6[U*8PP,XC#!"WS$$@8
M`/H:&[;CC%R=HJ[-&BL_1]<T[7[,W>FW`GA5RC':5(8=B#SW'YUH4)WV"47%
MVDK,**R;KQ)I=EKEOHT]P5OK@`QQ^6QR#G'.,=C6M233'*$HV;6X457O;ZUT
MZU>YO;B*W@3[TDC!0/SKDI_BIX7AE*+/<2C^\D#8_7%)RBMV73H5:GP1;.UK
MQ'XX6I77-*NC]V6V:/\`[Y;/_L]>I:+XOT/Q`_E6%\C3XSY,@*/^`/7\,UQW
MQKTXW'AJROU4DVESM8^BN,']0M:4I+F31QX^E*-*49*S10^&'Q#\[R/#VLS?
MO>$L[AS]_P!(V/KZ'OTZXSZY7Q_].#7T)\,?&;>)=(:QOI-VIV:@.Q/,T?0/
M]>Q]\'O6E6%M4<N"Q/-^[GOT.\HHK+UOQ%I?AV"*;5+GR4E8JF$9B3C/0`U@
MVEJSTXQE-\L5=FI138W$D:N`0&`(##!_$=JY_6/''A[0YF@N[]6N%.&BA4R,
MOUQP/H:&TM6.%.<WRP5V=%17&6OQ2\+W,H1KF>#)QNEA('YC.*Z^WN(;J!)[
M>:.:%QE)(V#*P]B*2DGLRJE&I3^.+1)114%Y>VNGVS7-Y<16\"?>DE8*!^)J
MC-)MV1/17%W'Q2\+P2%%N9Y@#C='`V/UQ5O3_B)X8U&80IJ(AD8X`N$,8/XG
MC]:CVD>YN\)72NX/[CJ:**YS4_'7A[1]1FL+V]:.YAQO40NV,@$<@8Z$53:6
MYE"G.H[05WY'1T5R/_"S/"G_`$$7_P#`>3_XFMO1/$&F^(;>6?3)S-'$^QR4
M9<'`/<#L:2G%Z)ESP]6"YI1:7H:=%8>M^+M%\/7,=OJ=TT,LB>8H$3-D9QV!
M]*U[:YAO+6*YMY%D@E0/&Z]&4C(-.Z;L0Z<XQ4FM&2T45D:9XGTG5]2NM/LK
MDR7-J6$J&-EVX;:>2,'FBZ0E"4DVEL:]%%%,D*X'XN_\BA!_U^I_Z"]=]7`_
M%W_D4(/^OU/_`$%ZBK\#.O`_[S#U.1\-7T_@37=.DN7/]D:Q:0RL[=%W*#GZ
MJQ(/^R<^E>V=1D5PUQX:3Q/\+]*M5"B[CL89+9SV<1CC/H1P?S[5'\,_$KZA
MIKZ)?%EO]/&T!^&:,''/NI^4_A44_=?+T9T8M*O%UE\479_HS,\3?\EGT'_K
ME%_Z%)7ILLJ00O+*P2-%+,QZ`#DFO,O$W_)9]!_ZY1?^A25UOCV=[?P-JSH2
M"8?+X]&8*?T)IQ=N9DUX<_L8=TE^)YU;QW_Q4\5R/-+)!H]H<A1_`AZ`#IO;
M!))Z<^@%>G67A'P_I]L((-(M"H')DB$C-]6;)-8'PHMHX?!@F4#?<7$CN?H=
MH_1:[FBG%6YGNQ8VO)5'2AI&.ECS3QI\.[9+1]7\/Q&UN[;]ZT$1(#`<Y3^Z
MPZC'7ZU/H.I'XA^`-2TF\93J"1>4SG@,>L<GYKS[J?6O1*\D\`QC3OB=K>GP
M\0!9U`]`L@V_D"12:Y)IKJ.,OK.&G"IJXZI^75'CDL4D$KPS(4EC8HZ,,%6!
MP0?QK6\+:[)X;\266IH3LC?$RC^*,\,/RY'N!7<?%WP>]CJ!\1646;2Y(%T%
M'^KEZ!OHW\_K7E]>DFI(^,J0E0J6['U\CK)&LB,&1@"K`\$'O7F'B,?\)5\5
M=.T8?/::<`\P[9X=OSPBUN^`M>CE^&=K?W3Y%A`\<I]!%D#_`,="UE_"NSEO
M&U;Q+=C]_>SLBGVSN?'MD@?\!KSZJ]Y0/K<#*U*6(\K+U?\`DBS\3/%EQH]I
M#I.G.R7UXN6=/O1QYQ\O^TQR`?8]\&E\(_#73]-LX[G6+>.[U!QN9)/FCB]@
M.A/J3GGI6%?QC4?CM!!/S'"Z%1_N0^8/_'J];J8KGDY/H;UIO#T84J>G,KM^
MI@ZGX+\/:K;&&;2[>,X^62!!&Z^X(_D<BO.=+N[_`.&OC$:3>3F72;E@=Q^[
MM8X$@'8@C##T'T->R5YI\9+6-]&TVZ(_>)<-$#_LLI)_]!%%6-ES+="P-9SG
M["H[QE^'FCT>XN(K6VEN)W"11(7=CV4#)/Y5X_8VVH?%3Q'+=7LLEOHUHV%C
M0_=!Z*.V\CDMV_*NI\57\Q^$0N"Q,MQ:6X=NA.\H&_/)_.KGPRMH[?P)9.@&
MZ=Y)7/J=Y'\E`_"B7OR4>FXZ/^ST)55\5^5>7<U+/P?X=L81'#HUF0!C=)$)
M&/U+9)JI?_#_`,,Z@Z.VF1P.KALV_P"[#8.<$#@@]#Q^5=-2,RK]Y@/J:TY(
M[6.-8BJGS*3OZB@8&!TKRAK&TU'XX7UM>VT5Q`8P3'*H921"F.#7J]>-:QK+
MZ#\8-0OX[*2\9451#&<$YA3GH>GTJ*ME:_<ZLO4I2J*._*_T/2O^$/\`#?\`
MT`M/_P#`=?\`"M#3]+L-*B>/3[."U1VW,L*!03C&3BN!_P"%J7G_`$*=]_WV
MW_Q%>@:==&^TRTO&B:%IX4E,3=4+`'!^F<547!_"8UZ>(IK][L_._P"IY?\`
M$NS74?'>A6+N46YC2(N!DJ&D(S^M7/ASK%QI&IW7@[53LF@=C;9[]V4>Q'SC
MV)]JC\=_\E-\,?[T/_HZKOQ-\/RM##XFTW,=]8$&5DZE`<AOJI_0GTK&S4G)
M=#T5*,Z-.A/:2T\G?0]$KRKX=?\`)0O$G^]-_P"CC7=^%?$$/B708+^/"R_<
MGC'\$@ZCZ=Q[$5PGPZ_Y*%XD_P!Z;_T<:N33<6CEH0E"E6C+=)?F>JT445L>
M<%<#\7?^10@_Z_4_]!>N^KC?B9I5_J_AF&WT^UDN9A=HY1,9"A6&>?J*BI\+
M.K!-1Q$&^YM>$_\`D3]%_P"O&'_T`5PGCW3+GPQXCM?&&E)\ID`N4'`W].?9
MAP??!ZFO0/#EO-:>&-*MKB,QS16D22(W56"`$5:U&PM]4TZ>QNTWP3H4<>Q[
MCW'44G'FC8JG7]E7<MT[W\T>6ZEJ5OJ_Q3\,ZA:-N@N+>)USU'S29!]P<@_2
MO1_$>FMK'AS4-/3_`%D\#*G./FQE?U`KR30_">M:/\0+&.:QNI;:UNL"Z6)C
M&4P2&ST'7\#FO;ZFE=IW-\<XTY4_9N]EI]YYC\(];3[)=:#<-LN(I#-$C<$J
M<!E^H(S^/M7IU>>>+_A_<W6I_P!N^')A;ZB&\QXMVS>W]Y3V8]P>#[<YI1>-
MO&^GH;>_\*RW,ZC`E2%P"?4[05/X8HC)P7+(*U&.*E[6BU=[INS3/1-5U.VT
M?2[C4+MML,"%F]3Z`>Y.`/K7FOPHM+B_UG5_$-PN/,)C!QP7=M[X^GR_G44N
MA^,_'MU$VLK_`&9IR-N$97;CW"$Y+>[8QSCTKT[2=*M-%TR#3[*/9!"N!DY)
M/<D]R3S0KSDGT1,N3#494T[SEO;HB>ZM8+ZTEM;J))8)5*21N,A@>H-?.WCW
MP)<>$;[SH-TNDSMB&4\F,_W&]_0]_P`Z^CZJZCIUKJVG3V%[$LMM.A1T/IZ^
MQ'4'L173";BSQL1AXUHVZGSYHFOO;_#S4="B.9[N_3:@/)0J,X_%%'_`C7O7
MA[2ET3P_8Z:N"8(@KD?Q/U8_B237D7A'P+>:?\3'LKJ&5K/3W^T+.4(64#F/
MGIG)4D>Q%>X5$E^\<CJHSM@J=+KJWZW:7X(\B\=>;X:^)&G^(0C&"78[%>Y4
M;'7Z[,?G7K%M<0WEM%<V\BR0RJ'1UZ,IY!K/\0Z!9^)-)DL+P$`G='(OWHW'
M1A_GD$UYS:6GCKP$SV]G:C5=-W$JJ*9`,]PH.Y3ZCD?7K6.L)-]&>A[N*I1C
M=*<=->J/6Z\D^*>I'6-:T_PW8'S9D<%P#QYK\*OX`DG_`'JLW/B[QWK*&UTS
MPW-8LXP9GC;(^C.%4?CFMCP3X!.A7!U7595N=4?)&"66+=U.3RS')R?<_4DF
MZGNQV*HTXX1^UJM<RV2=]?,V]>T#[;X)N-$M^66V6.'/=D`*_JHKD_A-K\3Z
M=+H$[;+F!VDA5N"R$Y8?4-G/U]C7I=>>>+_AY+?:@=;\/S_9M1W>8\>[8';^
M\K#[K?H?;G+G%IJ43+#U83A*A5=D]4^S/0Z\T^,P!T/3<_\`/RW_`*`:JP>+
M_'VD@6VH>'9+QDX\P6[Y;_@294_@*S]=_P"$T\>106TGATVD,,A=2ZM%R1CD
MN1D8]!4SFI1:2U-\+A94:T:DY+E76Z/7K/\`X\;?_KFO\J\WM/\`DO%[_P!<
MO_:*5Z7;HT5M%&V-RH%./4"O+M9L/$^G_$F^UW2-&:[0JJQL^-C`Q*I_B!Z@
MU539>IA@K.5172O%K7Y'JM%><?\`"3_$3_H5;?\`(_\`Q==+X4U/Q#J*79U_
M2X[`H5\D)_&#G/\`$>G'YU2FF[&-3"RIQYFU\FCD/'?_`"4WPQ_O0_\`HZO3
MW19$9'4,C##*PR"/0UP'C#1-3O\`Q]X?OK2RDFM;=HC+*N,)B7)SSZ<UZ#2@
MO>D:8F2=*DD]E^IY%:._PU\?-:RLPT34>58]$7/!^J$X/^R<^E6/AUQ\0O$O
M^]-_Z.-=EXU\-)XG\/R6R!1>1?O+9SV<?PY]"./R/:N,^%FD:KI^O7\VH:?>
M6RO;X#SQ,H9MP/4]36?*XS2Z'8JT*N&G-OW[)/SMLSU:BBBN@\8****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**IPZI:7-Z;2!Y)7",QD2
M)VB&URC+YH&S>&!!3.X8/%7*`"BBL_1-;T[Q'H\&K:3<?:+&?=Y<NQDW;6*G
MA@".01R*`-"BBB@`HHHH`**IWFJ6EC<6MO,\AGNGVQ1Q1/(QY`+$*"50%E!<
MX5=PR1D5<H`**S]*UO3M;^V_V=<>=]ANY+*X^1EV3)C<O(&<9'(R/>M"@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`KD_'>F:UJMOH<&C27:(NL6[Z@;6[-N
MWV3#"3+!E)'(X!STQTKK**`/"_"WA7XH1WNGCQ%J6LBW#QAO(O5E*PEY1+'*
MWVA,$JX;S%61U&S:5*;:Z#P[H'C>+6-%GU>;4GLYGMWO(GU(YM3;6AC^8*YW
MB:=MY"DC"*7R6(7U2B@#PM[WQ7=?%:;3=/UZ2>[:XU1D:"_$UK!$+=5MEEA4
MD1F.4X;?&,L>KFJ\7A/XH.;5)+WQ!Y0LKEI8VU%8@EU]FVQ[9%NG>0&55/S;
M5!)(50S`>^44`?/DWA7XP_V-,C:EK+:DR(B_9[V/RWCVQ':TC7"E'4HP+)'E
MCNR[A\CL_$FF>-;KQIIL&D65];Z%:2VUO+=IJK$W-L0PG+!IP0P#@!MC2$KN
M$@(45ZA10!\\>'_!/Q*TB/2+6"WU6TTRVB4:E:1:LB_:?]++N(-LN(V,97D&
M/[KC/S?-IZCX5^*D^CVZM?:E)?PZ%'&K6VJ^4/M?VO.&PZAG%N2"QR"1]YC@
MU[I10!XW\19O%=S\26TWPO/J37B:%%=VT%O>"*))5N\-(Z,ZHX*!EP0V=PXP
M,C#T'PC\1?#6GZ=9VVE7TMK+IYANX%UC:EM,;QG,B(MPF6\I5&$=`=YR>6!^
M@**`/"WT#XLR:9:3F;4AJ=IHZ)&%U)`K7:WN1O4/LD/V;J7!#=\M5B]T/XEV
M%^)]/MM2U""&]U*&*VEULHKVCH!;,Y\T,Q5GD8$GS/E`W+A"/;**`/'_``CH
M_P`0K?Q-#+XF35;C1(I9ELX(=15'@)EC9))\3EI(]N\;6DF(P1@C!.7;Z!\5
M;34M.N;F[UF\,6IQS:A#!=0K!<1)*[%HV:X!PRL!Y8CB0C;D97)]THH`^?-+
M\"_$BV\6^$=8G74C+&D4>KW$FK!V*"[=F0YD)9/*\L[5R#Z9S6W=Z5\15\+G
M35TW5;G6YI;A[S5EUG;&6!E\DV\:W$>U3O7(*JH"C,;D`#VBB@#P?3?#'Q'L
M/!L^;*^.NW&MSZA-;PWL4,-P'CC4F5XIHW7YB[*$;&5PRX*D>\444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
5%%`!1110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
